Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
HALAVEN (Eisai Inc.)
(https://halaven.com) 📸 Data Snapshot: May 30, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE HALAVEN® (eribulin mesylate) Injection: Treatment for Metastatic Breast Cancer (mBC) (https://halaven.com)
HALAVEN® (eribulin mesylate) Injection: Treatment for Metastatic Breast Cancer (mBC)
Learn about HALAVEN® (eribulin mesylate), an injectable treatment for patients with third-line Metastatic Breast Cancer (mBC). See the full Indication and Important Safety Information for HALAVEN®.
NAV_HEADER_REPEATED_FOOTER Metastatic Breast Cancer (mBC) Treatment | HALAVEN® (eribulin mesylate) Injection | HCP (https://halaven.com/hcp/metastatic-breast-cancer/)
Metastatic Breast Cancer (mBC) Treatment | HALAVEN® (eribulin mesylate) Injection | HCP
HCPs can learn about HALAVEN® (eribulin mesylate) Injection, a treatment for patients with third-line Metastatic Breast Cancer (mBC). View Important Safety Information and Prescribing Information.
NAV_HEADER_REPEATED What is HALAVEN® (eribulin mesylate) Injection | FDA-Approved Treatment for Metastatic Breast Cancer (mBC) | Patient (https://halaven.com/en/metastatic-breast-cancer/what-is-halaven/)
What is HALAVEN® (eribulin mesylate) Injection | FDA-Approved Treatment for Metastatic Breast Cancer (mBC) | Patient
Learn more about FDA-approved HALAVEN®, a chemotherapy treatment for metastatic breast cancer. Please see the full Indication and Important Safety Information for HALAVEN®.
NAV_HEADER_REPEATED Starting Treatment with HALAVEN® (eribulin mesylate) Injection (https://halaven.com/en/metastatic-breast-cancer/starting-halaven/)
Starting Treatment with HALAVEN® (eribulin mesylate) Injection
Read about the importance of working with your health care team while being treated with HALAVEN® (eribulin mesylate) injection for third-line Metastatic Breast Cancer (mBC). See the full Indication and Important Safety Information for HALAVEN®.
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://halaven.com) HALAVEN® (eribulin mesylate) Injection: Treatment for Metastatic Breast Cancer (mBC)
mBC blog [IMG: book] X Interested in articles and updates about metastatic breast cancer? Click here to read the mBC blog! [IMG: Halaven Patient Hero] [IMG: Live for the moments that haven] In a clinical study of more than 750 women, HALAVEN® was compared with other chemotherapies or hormone therapies commonly used to treat metastatic breast cancer (mBC). Although some women lived longer and some women did not live as long, women who were treated with HALAVEN lived, on average, 25% longer (13.2 months vs 10.6 months, respectively) than those who received another chemotherapy or hormone treatment. Learn more about the results [IMG: Arrow Image] × [H3] Inspire others with your journey on HALAVEN® (eribulin mesylate) Injection. Learn more by calling 757-528-3520 or emailing mBC@mypatientstory.com. There is a possibility that not all who submit their stories will be selected to participate. Any information provided will be kept in strict confidence according to our Privacy Policy, available at us.eisai.com/privacy-policy. [H4] Pay as little as $0* Learn about the $0 Co-Pay Program [IMG: Halaven website 0 co pay icon mobile] *The HALAVEN $0 Co-Pay Program assists eligible patients with the out-of-pocket costs of HALAVEN (up to $18,000 per year). Restrictions apply. Visit www.eisaireimbursement.com/patient/halaven/financial-assistance to see the full terms and conditions and eligibility requirements, to learn more about the program, and to download an enrollment form. Eligible commercially insured patients may pay as little as $0 per month, with an annual limit of $18,000. [IMG: mbc-blog-img] [IMG: mbc-blog-img-mob] [IMG: blog-book] mBC blog [H2] The Doctor Will See You Now: Making the Most of Your Next Virtual Visit [IMG: divider] Telehealth is here to stay. Here's what you need to know to make the most of your next virtual doctor's appointment. Read More [H4] Over 80,000 patients in the US have been prescribed HALAVEN for mBC Learn why [IMG: Halaven website prescribed icon mobile]
SUB-PAGE (https://halaven.com/hcp/metastatic-breast-cancer/) Metastatic Breast Cancer (mBC) Treatment | HALAVEN® (eribulin mesylate) Injection | HCP
HALAVEN® is the first and only single agent to show a significant overall survival benefit in patients with third-line metastatic breast cancer (mBC) that included all receptor subtypes.1-4 [H1] HALAVEN improved median overall survival in metastatic breast cancer vs Treatment of Physician's Choice (13.2 months vs 10.6 months) when following 2 prior chemotherapies for metastatic breast cancer.4 Learn About the HALAVEN $0 Co-Pay Program* *Subject to patient eligibility. [H3] Indications [H5] Metastatic Breast Cancer HALAVEN (eribulin mesylate) Injection is indicated for the treatment of patients with metastatic breast cancer (mBC) who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. [H5] Liposarcoma HALAVEN is indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. [H4] Important Safety Information [H5] Warnings and Precautions Neutropenia: Severe neutropenia (ANC <500/mm3) lasting >1 week occurred in 12% of patients with mBC and liposarcoma or leiomyosarcoma. Febrile neutropenia occurred in 5% of patients with mBC and 2 patients (0.4%) died from complications. Febrile neutropenia occurred in 0.9% of patients with liposarcoma or leiomyosarcoma, and fatal neutropenic sepsis occurred in 0.9% of patients. Patients with mBC with elevated liver enzymes >3 × ULN and bilirubin >1.5 × ULN experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal levels. Monitor complete blood cell counts prior to each dose, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Delay administration and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting >7 days. Peripheral Neuropathy: Grade 3 peripheral neuropathy occurred in 8% of patients with mBC (Grade 4=0.4%) and 22% developed a new or worsening neuropathy that had not recovered within a median follow-up duration of 269 days (range 25-662 days). Neuropathy lasting >1 year occurred in 5% of patients with mBC. Grade 3 peripheral neuropathy occurred in 3.1% of patients with liposarcoma and leiomyosarcoma receiving HALAVEN and neuropathy lasting more than 60 days occurred in 58% (38/65) of patients who had neuropathy at the last treatment visit. Patients should be monitored for signs of peripheral motor and sensory neuropathy. Withhold HALAVEN in patients who experience Grade 3 or 4 peripheral neuropathy until resolution to Grade 2 or less. Embryo-Fetal Toxicity: HALAVEN can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with HALAVEN and for at least 2 weeks following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with HALAVEN and for 3.5 months following the final dose. QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. Correct hypokalemia or hypomagnesemia prior to initiating HALAVEN and monitor these electrolytes periodically during therapy. Avoid in patients with congenital long QT syndrome. [H5] Adverse Reactions In patients with mBC receiving HALAVEN, the most common adverse reactions (≥25%) were neutropenia (82%), anemia (58%), asthenia/fatigue (54%), alopecia (45%), peripheral neuropathy (35%), nausea (35%), and constipation (25%). Febrile neutropenia (4%) and neutropenia (2%) were the most common serious adverse reactions. The most common adverse reaction resulting in discontinuation was peripheral neuropathy (5%). In patients with liposarcoma and leiomyosarcoma receiving HALAVEN, the most common adverse reactions (≥25%) reported in patients receiving HALAVEN were fatigue (62%), nausea (41%), alopecia (35%), constipation (32%), peripheral neuropathy (29%), abdominal pain (29%), and pyrexia (28%). The most common (≥5%) Grade 3-4 laboratory abnormalities reported in patients receiving HALAVEN were neutropenia (32%), hypokalemia (5.4%), and hypocalcemia (5%). Neutropenia (4.9%) and pyrexia (4.5%) were the most common serious adverse reactions. The most common adverse reactions resulting in discontinuation were fatigue and thrombocytopenia (0.9% each). [H5] Use in Specific Populations Lactation: Because of the potential for serious adverse reactions in breastfed infants from eribulin mesylate, advise women not to breastfeed during treatment with HALAVEN and for 2 weeks after the final dose. Hepatic and Renal Impairment: A reduction in starting dose is recommended for patients with mild or moderate hepatic impairment and/or moderate or severe renal impairment. Full Prescribing Information [IMG: Full Prescribing Information] [H3] Indications [H5] Metastatic Breast Cancer HALAVEN (eribulin mesylate) Injection is indicated for the treatment of patients with metastatic breast cancer (mBC) who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. [H5] Liposarcoma HALAVEN is indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. Tap to expand Important Safety Information Tap to close Important Safety Information [H3] Indications [H5] Metastatic Breast Cancer HALAVEN (eribulin mesylate) Injection is indicated for the treatment of patients with metastatic breast cancer (mBC) who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. [H5] Liposarcoma HALAVEN is indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. [H4] Important Safety Information [H5] Warnings and Precautions Neutropenia: Severe neutropenia (ANC <500/mm3) lasting >1 week occurred in 12% of patients with mBC and liposarcoma or leiomyosarcoma. Febrile neutropenia occurred in 5% of patients with mBC and 2 patients (0.4%) died from complications. Febrile neutropenia occurred in 0.9% of patients with liposarcoma or leiomyosarcoma, and fatal neutropenic sepsis occurred in 0.9% of patients. Patients with mBC with elevated liver enzymes >3 × ULN and bilirubin >1.5 × ULN experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal levels. Monitor complete blood cell counts prior to each dose, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Delay administration and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting >7 days. Peripheral Neuropathy: Grade 3 peripheral neuropathy occurred in 8% of patients with mBC (Grade 4=0.4%) and 22% developed a new or worsening neuropathy that had not recovered within a median follow-up duration of 269 days (range 25-662 days). Neuropathy lasting >1 year occurred in 5% of patients with mBC. Grade 3 peripheral neuropathy occurred in 3.1% of patients with liposarcoma and leiomyosarcoma receiving HALAVEN and neuropathy lasting more than 60 days occurred in 58% (38/65) of patients who had neuropathy at the last treatment visit. Patients should be monitored for signs of peripheral motor and sensory neuropathy. Withhold HALAVEN in patients who experience Grade 3 or 4 peripheral neuropathy until resolution to Grade 2 or less. Embryo-Fetal Toxicity: HALAVEN can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with HALAVEN and for at least 2 weeks following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with HALAVEN and for 3.5 months following the final dose. QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. Correct hypokalemia or hypomagnesemia prior to initiating HALAVEN and monitor these electrolytes periodically during therapy. Avoid in patients with congenital long QT syndrome. [H5] Adverse Reactions In patients with mBC receiving HALAVEN, the most common adverse reactions (≥25%) were neutropenia (82%), anemia (58%), asthenia/fatigue (54%), alopecia (45%), peripheral neuropathy (35%), nausea (35%), and constipation (25%). Febrile neutropenia (4%) and neutropenia (2%) were the most common serious adverse reactions. The most common adverse reaction resulting in discontinuation was peripheral neuropathy (5%). In patients with liposarcoma and leiomyosarcoma receiving HALAVEN, the most common adverse reactions (≥25%) reported in patients receiving HALAVEN were fatigue (62%), nausea (41%), alopecia (35%), constipation (32%), peripheral neuropathy (29%), abdominal pain (29%), and pyrexia (28%). The most common (≥5%) Grade 3-4 laboratory abnormalities reported in patients receiving HALAVEN were neutropenia (32%), hypokalemia (5.4%), and hypocalcemia (5%). Neutropenia (4.9%) and pyrexia (4.5%) were the most common serious adverse reactions. The most common adverse reactions resulting in discontinuation were fatigue and thrombocytopenia (0.9% each). [H5] Use in Specific Populations Lactation: Because of the potential for serious adverse reactions in breastfed infants from eribulin mesylate, advise women not to breastfeed during treatment with HALAVEN and for 2 weeks after the final dose. Hepatic and Renal Impairment: A reduction in starting dose is recommended for patients with mild or moderate hepatic impairment and/or moderate or severe renal impairment. Full Prescribing Information [IMG: Full Prescribing Information] References: 1. Cortes J, O’Shaughnessy J, Loesch D, et al; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914-923. 2. Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol. 2010;28(11):1958-1962. 3. Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010;28(20):3256-3263. 4. HALAVEN [package insert]. Nutley, NJ: Eisai Inc. 5. Data on file, Eisai Inc.
SUB-PAGE (https://halaven.com/en/metastatic-breast-cancer/what-is-halaven/) What is HALAVEN® (eribulin mesylate) Injection | FDA-Approved Treatment for Metastatic Breast Cancer (mBC) | Patient
[H2] What is HALAVEN®? HALAVEN is an FDA-approved chemotherapy that offers women with advancing mBC an opportunity to live longer after progressing on 2 other therapies.* *Therapies should have included an anthracycline and a taxane for early or advanced breast cancer. [IMG: halaven microscope] HALAVEN is developed from a natural substance found in a sea sponge, and is the only medicine discovered in its class of chemotherapy. [H4] How does HALAVEN work? Based on early laboratory studies, HALAVEN works by [IMG: How halaven works desktop image] [IMG: How halaven works mobile image] Tumor cells left behind may then be made less likely to spread. [IMG: ask your doctor cta desktop] [IMG: ask your doctor cta mobile] [IMG: clinical study of women with metastatic breast cancer]
SUB-PAGE (https://halaven.com/en/metastatic-breast-cancer/starting-halaven/) Starting Treatment with HALAVEN® (eribulin mesylate) Injection
[H2] I’m starting HALAVEN® treatment for metastatic breast cancer If you and your health care provider (HCP) decide that HALAVEN is the right treatment for you, he or she will review your treatment schedule with you and discuss what you can expect from treatment. [H4] Before starting HALAVEN Be sure to tell your HCP about all of your medical conditions, including if you have Liver or kidney problems Heart problems, including a problem called “congenital long QT syndrome” Low potassium or low magnesium in your blood And be sure to let your HCP know if you are currently Pregnant or plan to become pregnant. Talk with your HCP about birth control methods Breastfeeding or planning to breastfeed Tell your HCP about all of the medicines you are taking or if you are planning to take any new medicines, including Prescription medicines Medicines that you buy without a prescription (over the counter) Vitamins Herbal supplements [IMG: Starting HALAVEN treatment] To see the HALAVEN dosing schedule and understand what your own treatment schedule might look like, click here.
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 1 | 1 |
| /hcp/metastatic-breast-cancer/ | 1 | 0 |
| /en/metastatic-breast-cancer/what-is-halaven/ | 1 | 1 |
| /en/metastatic-breast-cancer/starting-halaven/ | 2 | 1 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: HALAVEN (Eisai Inc.) (halaven.com)
A high-substance, low-BS pharmaceutical site that functions more like a legal disclosure than a marketing brochure. It relies on aging but peer-reviewed clinical data and massive blocks of safety data to anchor its life-extension claims. The site’s only significant failures are its stale clinical references and poor technical schema implementation.
Integrate Organization and MedicalWebPage schema to bridge the technical authority gap. Update the primary clinical data section to include real-world evidence (RWE) from the last 36 months to modernize the proof density. Consolidate the redundant safety headings into a single ‘Safety & Indications’ mega-nav to improve mobile hierarchy. Replace the ‘data on file’ citation for the 80,000 patients claim with a link to an annual report or transparent prescribing audit.
The website perfectly matches the Pharma & Biotech category. It focuses exclusively on the therapeutic area of metastatic breast cancer and liposarcoma, utilizing specific pharmaceutical identifiers like eribulin mesylate and referencing Phase 3 clinical trial data.
“The score of 27 is driven primarily by the high information density and lack of semantic drift, which are standard for highly regulated biotech products. Penalties were applied for 'stale' evidence (2011 citations), the lack of structured data (schema), and the use of 'trust theatre' elements like patient story 'reviews' without external verification. Overall, the site remains firmly in the 'Minimal to Low BS' category.”
This training module utilizes a snapshot of public data from HALAVEN (Eisai Inc.), captured on May 30, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to HALAVEN (Eisai Inc.): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://halaven.com to view the most current version of its content and learn from the source what this company is about and what it offers.